P144, A TGF-β1 Antagonist Peptide, Synergizes with Sildenafil and Enhances Erectile Response via Amelioration of Cavernosal Fibrosis in Diabetic Rats
- 1 December 2013
- journal article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 10 (12) , 2942-2951
Abstract
Introduction: Patients with diabetes exhibit more severe erectile dysfunction (ED) and are less responsive to first-line oral phosphodiesterase type 5 inhibitor (PDE5i). It has been suggested that increased collagen deposition and reduced smooth muscle content in the corpus cavernosum are important mechanisms for diabetes-associated ED and that transforming growth factor-β1 (TGF-β1) is a potent fibrotic factor responsible for the structural alterations in the corpus cavernosum. Aims: The aims of this study are to determine whether activation of TGF-β1 and its downstream pathways is responsible for the reduced efficacy of the PDE5is in diabetic ED via abnormalities in cavernosal structures and to investigate the synergistic effects of the TGF-β1 antagonist P144 and sildenafil on erectile response. Methods: Six weeks after inducting diabetes with streptozotocin in male Sprague-Dawley rats, age-matched control and diabetic rats were treated with vehicle, sildenafil, or P144 alone or in combination for 4 weeks, respectively. Main Outcome Measures: Intracavernous pressure, dynamic infusion cavernosometry, and histological and molecular alterations of the corpus cavernosum were analyzed. Results: Diabetic rats exhibited a decreased erectile response, severe corporal veno-occlusive dysfunction (CVOD), and structural alterations including cavernosal fibrosis and decreased smooth muscle content. Expression and activation of TGF-β1 and its downstream Smad and non-Smad pathways increased in diabetic rats. Treatment with sildenafil showed modest effect on erectile response and a less suppressive effect on CVOD, cavernosal fibrosis, and molecular alterations. Treatment with P144 had lower effect on erectile response, even greatly improved the histological and molecular alterations and CVOD than sildenafil. The combined treatment with P144 and sildenafil effectively restored erectile response, CVOD, and histological and molecular alterations. Conclusion: An insufficient suppressive effect of sildenafil on cavernosal fibrosis, severe CVOD, and TGF-β1 pathways was implicated in reduced efficacy of the PDE5i in diabetic ED. Treatment with P144 synergized sildenafil and significantly increased erectile response by the potential antifibrotic activity.Keywords
Funding Information
- the Natural Science Foundation of China (81070544, 81172450)
- China Postdoctoral Science Foundation (20100480585)
- Science and Technology Commission of Shanghai Municipality (12ZR1416700)
- the Natural Science Foundation of China (81070544, 81172450)
- China Postdoctoral Science Foundation (20100480585)
- Natural Science Foundation of Science and Technology Commission of Shanghai Municipality (12ZR1416700)
This publication has 35 references indexed in Scilit:
- Amelioration of Penile Fibrosis: Myth or RealityJournal of Andrology, 2010
- Testosterone and chronic sildenafil/tadalafil anti-apoptotic role in aged diabetic ratsInternational Journal Of Impotence Research, 2010
- Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in ratsInternational Journal Of Impotence Research, 2007
- Long-Term Continuous Treatment with Sildenafil Ameliorates Aging-Related Erectile Dysfunction and the Underlying Corporal Fibrosis in the Rat1Biology of Reproduction, 2007
- Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the ratUrology, 2006
- Corporal veno-occlusive dysfunction in aging rats: Evaluation by cavernosometry and cavernosographyUrology, 2004
- Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trialsDiabetologia, 2004
- Do Impotent Men With Diabetes Have More Severe Erectile Dysfunction and Worse Quality of Life Than the General Population of Impotent Patients?Diabetes Care, 2003
- Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitusInternational Journal Of Impotence Research, 2002
- Comparative Results of Goal Oriented Therapy for Erectile DysfunctionJournal of Urology, 1997